Medicamen Biotech Share Price
264.10+4.70 (+1.81%)
-24.66% past 1 Year
Medicamen Biotech Limited is engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets. It is a manufacturer and supplier of a range of products such as
Corporate filings & documents
Announcements
Reg 34 (1) Annual Report
20 hours agoReg 34 (1) Annual Report
20 hours agoBusiness Responsibilty and Sustainability Report - 2025-26
21 hours agoBusiness Responsibilty and Sustainability Report - 2025-26
21 hours agoSubmission of Integrated Annual Report for FY 2025-26
21 hours agoSubmission of Integrated Annual Report for FY 2025-26
21 hours agoNotice of 33rd AGM scheduled to be held on Saturday September 26 2026 through video conferencing/other audio visual means ("VC/OAVM")
21 hours agoNotice of 33rd AGM scheduled to be held on Saturday September 26 2026 through video conferencing/other audio visual means ("VC/OAVM")
21 hours agoThe Company has fixed Saturday September 19 2026 as the record date for determining the entitlement of members to receive the dividend if declared at the ensuing AGM.
2 weeks agoThe Company has fixed Saturday September 19 2026 as the record date for determining the entitlement of members to receive the dividend if declared at the ensuing AGM.
2 weeks agoCorporate Action- Fixes Record Date as September 19 2026 for the purpose of declaration of final dividend for FY 2025-26.
2 weeks agoCorporate Action- Fixes Record Date as September 19 2026 for the purpose of declaration of final dividend for FY 2025-26.
2 weeks agoAnnouncement under Regulation 30 (LODR)- Newspaper Publication for the Unaudited Standalone and Consolidated Financial Results for the Qtr ended 30.06.2026
2 weeks agoAnnouncement under Regulation 30 (LODR)- Newspaper Publication for the Unaudited Standalone and Consolidated Financial Results for the Qtr ended 30.06.2026
2 weeks agoBoard of Directors has been approved the closure of Register of Members and Share Transfer Books from September 19 2026 to September 25 2026 in connection with the proposed payment of final dividend @ 10% i.e Rs. 1 per Equity Share subject to approval of the members at the forthcoming AGM.
2 weeks agoBoard of Directors has been approved the closure of Register of Members and Share Transfer Books from September 19 2026 to September 25 2026 in connection with the proposed payment of final dividend @ 10% i.e Rs. 1 per Equity Share subject to approval of the members at the forthcoming AGM.
2 weeks agoFinancial Results for the quarter ended on June 30 2026.
2 weeks agoFinancial Results for the quarter ended on June 30 2026.
2 weeks agoMedicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 inter alia to consider and approve the Unaudited Financial Results for the quarter ended 30 June 2026.
3 weeks agoMedicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 inter alia to consider and approve the Unaudited Financial Results for the quarter ended 30 June 2026.
3 weeks agoCompliance Certificate under Reg 74(5) of SEBI (DP) Regulations 2018
1 month agoCompliance Certificate under Reg 74(5) of SEBI (DP) Regulations 2018
1 month agoIntimation for closure of trading window
2 months agoIntimation for closure of trading window
2 months agoThe Board of Directors of the comoany at the meeting held on Wednesday May 27 2026 recommnded payment of Final Dividend of Rs. 1.00 per Equity Share of the face value of Rs. 10.00 each for the financial year ended March 31 2026 subject to approval of the shareholders at the ensuing Annual General Meeting of the Company.
3 months agoThe Board of Directors of the comoany at the meeting held on Wednesday May 27 2026 recommnded payment of Final Dividend of Rs. 1.00 per Equity Share of the face value of Rs. 10.00 each for the financial year ended March 31 2026 subject to approval of the shareholders at the ensuing Annual General Meeting of the Company.
3 months agoStatement of Deviation & Variation Report - March 31 2026
3 months agoStatement of Deviation & Variation Report - March 31 2026
3 months agoAnnouncement under Regulation 30 (LODR) - Newspaper Publication for BM held on 27.05.2026
3 months agoAnnouncement under Regulation 30 (LODR) - Newspaper Publication for BM held on 27.05.2026
3 months agoAudited Standalone & Consolidated Financial Results for the quarter and year ended on March 31 2026
3 months agoAudited Standalone & Consolidated Financial Results for the quarter and year ended on March 31 2026
3 months agoMedicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 inter alia to consider and approve the audited financial results (Standalone and Consolidated) for the quarter and year ended on March 31 2026 and for recommendation of Final Divided for FY 2025-26 on Equity Shares of the Company.
3 months agoCompliance Certifcate under Reg 74 (5) of SEBI (DP) Regulation 2018
4 months agoCompliance Certifcate under Reg 74 (5) of SEBI (DP) Regulation 2018
4 months agoIntimation regarding Incorrent Event Display on NSDL Portal
5 months agoIntimation regarding Incorrent Event Display on NSDL Portal
5 months agoIntimation of Closure of Trading Window - March 2026
5 months agoIntimation of Closure of Trading Window - March 2026
5 months agoThe company has on 27.01.2026 received a cautionery letter (Email) from NSE for observations reported by the Secretarial Auditor in ASCR for FY ended 31.03.2025.
6 months agoThe company has on 27.01.2026 received a cautionery letter (Email) from NSE for observations reported by the Secretarial Auditor in ASCR for FY ended 31.03.2025.
6 months agoCorrigendum- Intimation regarding completion of term of Independent Directorship of Mr Harish Pande and Mr Arun Kumar
6 months agoAnnouncement under Regulation 30 (LODR) - Newspaper Publication
6 months agoAnnouncement under Regulation 30 (LODR) - Newspaper Publication
6 months agoPursuant to Regulation 30 of the SEBI (Listing Obligatons and Disclosure Requirements) Regulations 2025 the Company hereby informs that Mr. Harish Pande and Mr. Arun Kumar have completed their term as an Independent Directors of the Company.
6 months agoPursuant to Regulation 30 of the SEBI (Listing Obligatons and Disclosure Requirements) Regulations 2025 the Company hereby informs that Mr. Harish Pande and Mr. Arun Kumar have completed their term as an Independent Directors of the Company.
6 months agoUnaudited Financial Results for the quarter ended on December 31 2025
6 months agoMedicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 inter alia to consider and approve the unaudited consolidated and standalone financial results of the Company for the quarter and nine months ended on December 31 2025.
7 months agoCompliance- Certificate under Reg 74 (5) of SEBI (DP) Regulations 2018
7 months agoAnnouncement under Regulation 30 (LODR) - EU approval for product registration of Paracetamol from Danish Medicine Authority with XGX Pharma - Denmark
7 months agoAnnual reports
Concalls & investor presentations
Nov 2024
ConcallPresentation
Nov 2020
ConcallPresentation
Corporate Actions
Date
Type
Details
2026-09-18
Dividend
1.0
2025-09-26
Dividend
1.0
2025-09-19
Dividend
1.0
2024-09-19
Dividend
1.0
2023-09-20
Dividend
1.0
Company details
Registered office
1506 Chiranjiv Tower 43, Nehru Place New Delhi Delhi PIN: 110019 Tel No: 011-47589500-51 Fax No: 011-26213081 Email: [email protected] Internet: www.medicamen.com
Registrars
Noble Heights, 1st Floor, Plot NH 2C-1 Block LSC, Near Savitri MarketJanakpuriNew Delhi-11005891-4141-0592/93/9491-4141-0591 Noble Heights, 1st Floor, Plot NH 2 C-1 Block LSC, Near Savitri Market Janakpuri PIN: Tel No: 91-4141-0592/93/94 Fax No: 91-4141-0591 Email: [email protected] Internet: https://in.mpms.mufg.com/
Management
Rahul Bishnoi, Chairman
Vimal Kumar Shrawat, Non Independent & Non Executive Director
Ashwani Kumar Sharma, Non Independent & Non Executive Director
Suresh Kumar Singh, Non Independent & Non Executive Director
Sanjay Bansal, Non Independent & Non Executive Director
Ravi Kumar Bansal, Non Executive Independent Director
Sumita Dwivedi, Non Executive Independent Director
Sham Goel, Non Executive Independent Director
Parul Choudhary, Company Secretary & Compliance Officer
Shaival Saurabh, Non Executive Independent Director
Details
BSE 531146
NSE MEDICAMEQ
ISIN INE646B01010